文献速递哮喘

2型炎症生物标志物诊断哮喘的准确性:30项研究的荟萃分析及成人初级保健队列前瞻性验证

Accuracy of type 2 inflammatory biomarkers to diagnose asthma in adults and children: a meta-analysis of 30 studies with prospective validation in an adult primary care cohort.
PubMed 文献 · Lancet Respir Med · 2026-09-15

该系统综述与荟萃分析纳入22项成人研究和9项儿童研究,评估FeNO和血嗜酸性粒细胞计数对疑似哮喘且肺功能正常的患者的诊断准确性。血嗜酸性粒细胞单独诊断准确性弱且不增加FeNO价值。DIVE前瞻性成人初级保健队列验证了上述阈值。

要点

  • 初级保健20%患病率下,FeNO≥65 ppb阳性预测值80%,<20 ppb阴性预测值93%。

核心结论

  • 在疑似哮喘的成人和儿童中,FeNO可预测气道高反应性,并提供临床适用的 rule-in 和 rule-out 阈值。
  • 血嗜酸性粒细胞单独诊断性能差,且不增加FeNO的诊断价值。
  • 上述发现和阈值在成人初级保健前瞻性队列中得到重复验证。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE等数据库至2024年6月4日,纳入诊断性研究(随机试验、队列、横断面、病例对照或病例系列)。
  • 纳入年龄≥5岁、疑似哮喘且肺功能正常的患者,比较FeNO或血嗜酸性粒细胞与支气管激发试验或支气管舒张试验联合激发试验的诊断准确性。
  • 共纳入22项成人研究(7141例)和9项儿童研究(989例),总计30项研究(1项同时纳入成人和儿童)。
  • DIVE为单中心前瞻性队列,在初级保健转诊、支气管舒张试验阴性的成人中复制分析,患者在接受标准化乙酰甲胆碱支气管激发试验前立即检测FeNO和血嗜酸性粒细胞。

主要发现

  • 在反映初级保健的20%患病率下,FeNO≥65 ppb的阳性预测值为80%(95% CI 72-86),FeNO<20 ppb的阴性预测值为93%(95% CI 91-94),漏诊率为18%(95% CI 12-25)。
  • 儿童在汇总研究患病率56%下,FeNO≥30 ppb的阳性预测值为80%(95% CI 73-84)。

关键数值与推荐

  • 初级保健20%患病率下,成人FeNO≥65 ppb:阳性预测值80%(95% CI 72-86);FeNO<20 ppb:阴性预测值93%(95% CI 91-94),漏诊率18%(95% CI 12-25)。
  • 儿童56%患病率下,FeNO≥30 ppb:阳性预测值80%(95% CI 73-84)。
  • DIVE验证:FeNO>65 ppb阳性预测值73%(95% CI 39-94),FeNO<20 ppb阴性预测值92%(95% CI 82-97),总体准确率89%。

临床怎么用

  • 在疑似哮喘且肺功能正常的成人中,可采用FeNO阈值辅助 rule-in(如≥65 ppb)和 rule-out(如<20 ppb)决策。
  • 血嗜酸性粒细胞不建议单独用于哮喘诊断,也不增加FeNO的诊断价值。
  • 解读FeNO结果时应考虑近期吸入糖皮质激素暴露,暴露后2周内诊断准确性下降。

局限性

  • 儿童中尚无与DIVE类似的前瞻性验证研究,相关研究正在进行中。
  • rule-out阈值(如FeNO<20 ppb)为事后分析得出。
  • 吸入糖皮质激素暴露对诊断准确性的影响为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma diagnosis is challenging, partly due to low yield of bronchodilator reversibility and limited access to bronchial provocation tests (BPTs). Fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC) have been proposed as rule-in biomarkers. We aimed to evaluate the diagnostic accuracy of these biomarkers in adults and children, focusing on primary care applicability. METHODS: In this systematic review and meta-analysis, we searched MEDLINEand other databases from inception to June 4, 2024, for eligible diagnostic studies (randomised trials, cohort, cross-sectional, case-control, or case series). We included studies comparing FeNO or BEC with BPT or bronchodilator reversibility plus BPT in patients aged 5 years or older with suspected asthma and normal spirometry. Diagnostic performance in adults (aged ≥18 years) and children (aged 5-17 years) was estimated by the primary outcome measure of area under the receiver operating characteristic curve (AUC). Rule-in thresholds (prespecified) and rule-out thresholds (post hoc) were derived. In a single-centre cohort study (DIVE), analyses were prospectively replicated in bronchodilator reversibility-negative individuals referred for a BPT by primary care. Patients underwent FeNO and BEC immediately before a standardised methacholine BPT. The primary outcome for DIVE was biomarker performance for positive BPT, ascertained by AUC for FeNO, BEC, and the combination of FeNO and BEC. Post-hoc analyses addressed potential confounding by inhaled corticosteroid exposure. The systematic review and meta-analysis was registered with PROSPERO (CRD42023489738). The DIVE study was registered with ClinicalTrials.gov (NCT05592519). FINDINGS: 22 adult studies with 7141 patients and nine paediatric studies with 989 patients were included for meta-analysis (30 studies overall, with one study in both adults and children). FeNO diagnostic accuracy was good in adults (AUC 0·80 [95% CI 0·73-0·85]) and fair in children (0·75 [0·65-0·82]). In adults, FeNO of 48 ppb or higher achieved a positive likelihood ratio of 10·1 (95% CI 8·9-11·2). At a 20% prevalence reflecting primary care, a FeNO of 65 ppb or higher achieved a positive predictive value (PPV) of 80% (95% CI 72-86), and FeNO of less than 20 ppb achieved a negative predictive value of 93% (91-94) with 18% (12-25) missed diagnoses. In children, at the 56% aggregated study prevalence, FeNO of 30 ppb or higher achieved a PPV of 80% (95% CI 73-84). In adults, BEC showed weak stand-alone accuracy (AUC 0·65 [95% CI 0·59-0·71]) and added no value to FeNO. The DIVE cohort study (22 [18%] of 123 patients BPT positive) validated results of the meta-analysis in adults, with similar AUCs (0·77 [95% CI 0·65-0·89] for FeNO alone and 0·67 [0·53-0·80] for BEC alone). FeNO thresholds correctly classifyied rule-in decisions (FeNO >65 ppb: PPV 73% [95% CI 39-94]) and rule-out decisions (FeNO <20 ppb: NPV 92% [82-97]) with 89% overall accuracy. In both the meta-analysis and the DIVE cohort, FeNO diagnostic accuracy declined within 2 weeks of inhaled corticosteroid exposure. INTERPRETATION: In adults and children with suspected asthma, FeNO predicted airway hyper-responsiveness and enabled clinically applicable rule-in and rule-out thresholds. BEC performed poorly alone and added no value to FeNO. Findings and thresholds were replicated in a prospective adult primary care cohort; a similar study in children is ongoing. FeNO-guided diagnostic algorithms using context-specific rule-in and rule-out thresholds, while accounting for recent inhaled corticosteroid exposure, warrant consideration. FUNDING: Fonds de Recherche du Québec-Santé, Association Pulmonaire du Québec, Québec Ministry of Health and Social Services, AstraZeneca, Opération Enfant Soleil, and NIOX Group.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Roy MA, Gronnier M, Désy L, et al. Accuracy of type 2 inflammatory biomarkers to diagnose asthma in adults and children: a meta-analysis of 30 studies with prospective validation in an adult primary care cohort. Lancet Respir Med. 2026. PMID: 42743935. doi:10.1016/S2213-2600(26)00228-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。